ETRADE Capital Management LLC acquired a new stake in PRA Health Sciences (NASDAQ:PRAH) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 2,702 shares of the medical research company’s stock, valued at approximately $246,000.
Several other institutional investors and hedge funds have also recently made changes to their positions in PRAH. IFP Advisors Inc lifted its stake in shares of PRA Health Sciences by 19,083.3% in the fourth quarter. IFP Advisors Inc now owns 1,151 shares of the medical research company’s stock valued at $105,000 after purchasing an additional 1,145 shares during the period. Intrust Bank NA acquired a new position in shares of PRA Health Sciences in the fourth quarter valued at approximately $204,000. Comerica Bank acquired a new position in shares of PRA Health Sciences in the third quarter valued at approximately $214,000. Parametrica Management Ltd purchased a new stake in PRA Health Sciences in the fourth quarter valued at approximately $232,000. Finally, Vident Investment Advisory LLC purchased a new stake in PRA Health Sciences in the third quarter valued at approximately $247,000. Institutional investors and hedge funds own 99.22% of the company’s stock.
Several research analysts have recently weighed in on PRAH shares. BidaskClub upgraded shares of PRA Health Sciences from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, January 23rd. Mizuho cut shares of PRA Health Sciences from a “buy” rating to a “neutral” rating and set a $86.00 price target on the stock. in a report on Wednesday, January 24th. Zacks Investment Research cut shares of PRA Health Sciences from a “buy” rating to a “hold” rating in a report on Thursday, January 18th. Finally, KeyCorp restated a “buy” rating and set a $100.00 price target on shares of PRA Health Sciences in a research report on Wednesday, January 31st. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. PRA Health Sciences currently has an average rating of “Buy” and an average price target of $95.67.
In related news, VP Linda Baddour sold 67,000 shares of PRA Health Sciences stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $90.27, for a total value of $6,048,090.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 2.10% of the company’s stock.
PRAH stock traded down $1.94 during midday trading on Friday, hitting $81.38. 362,262 shares of the company traded hands, compared to its average volume of 434,765. The company has a market cap of $5,325.90, a PE ratio of 25.43, a price-to-earnings-growth ratio of 1.31 and a beta of 0.49. The company has a quick ratio of 0.90, a current ratio of 0.90 and a debt-to-equity ratio of 1.31. PRA Health Sciences has a twelve month low of $61.93 and a twelve month high of $95.90.
PRA Health Sciences (NASDAQ:PRAH) last issued its earnings results on Wednesday, February 21st. The medical research company reported $1.04 EPS for the quarter, topping the consensus estimate of $1.02 by $0.02. The firm had revenue of $568.80 million during the quarter, compared to analysts’ expectations of $543.78 million. PRA Health Sciences had a return on equity of 22.77% and a net margin of 3.85%. PRA Health Sciences’s quarterly revenue was up 37.5% compared to the same quarter last year. During the same period last year, the business earned $0.71 earnings per share. equities analysts expect that PRA Health Sciences will post 3.81 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: “ETRADE Capital Management LLC Buys New Position in PRA Health Sciences (NASDAQ:PRAH)” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The correct version of this report can be read at https://www.dispatchtribunal.com/2018/04/07/etrade-capital-management-llc-purchases-new-position-in-pra-health-sciences-inc-prah.html.
About PRA Health Sciences
PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.
Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.